Professional background

I trained at Newcastle University and undertook research in Melbourne, Australia. I moved to London and was appointed consultant/honorary senior lecturer in thoracic medicine at UCLH/UCL in 1998. I was clinical lead for respiratory medicine from 2006-2018. I have been clinical lead for tuberculosis at UCLH since 1998 and at North Central London-South Hub (based at the Whittington Hospital) since 2014 when TB services in the sector were amalgamated.

As lead clinician for the TB service, I work with colleagues to provide an accessible, prompt and effective clinical service for patients with TB and non-tuberculous mycobacteria, and research including how to improve adherence/support for patients with TB, understand why people develop TB disease and developing more accurate tests for TB. UCLH/South Hub is a designated centre for the management of MDR/XDR-TB.

I have clinical and research interests in interstitial lung disease, particularly sarcoidosis, and work with colleagues in the Centre for Respiratory Research at UCL. I provide joint care with other disciplines, e.g. cardiology and neurology, for patients with non-pulmonary sarcoidosis.

I undertake inpatient care of patients with general/respiratory medical problems, many of whom have airway diseases such as asthma (which was my initial area of research) and COPD. I have worked to improve clinical outcomes for these patients by setting up integrated care with community teams and participation in the National COPD audit.

I support the comprehensive diagnostic and therapeutic bronchoscopy service provided at UCLH.


  • Sarcoidosis – a neglected disease? H Booth Br J Hosp Med (Lond). 2020 Oct 2;81(10):1-5
  • Identification of a novel HIF-1?-?M?2 integrin-NETosis axis in fibrotic interstitial lung disease Akif A, et al. Frontiers in Immunology 2020 (in press)
  • Genome-Wide Association Study of Susceptibility to Idiopathic Pulmonary Fibrosis. Allen RJ, et al Am J Respir Crit Care Med. 2020 Mar 1;201(5):564-574
  • Developing a pathway for the diagnosis and management of ocular tuberculosis. The pan-LOndon Ocular tuberculosis Pathway-LOOP. Petrushkin H, et al Eye (Lond). 2020 May;34(5):805-808
  • Fluoroquinolones and isoniazid-resistant tuberculosis: implications for the 2018 WHO guidance. Stagg HR, et al Eur Respir J. 2019 Oct 10;54(4):1900982
  • Acquired Adult Aerodigestive Fistula: Classification and Management. Qureshi YA, et al J Gastrointest Surg. 2018 Oct;22(10):1785-1794.
  • Direct Whole-Genome Sequencing of Sputum Accurately Identifies Drug-Resistant Mycobacterium tuberculosis Faster than MGIT Culture Sequencing. Doyle RM, et al J Clin Microbiol. 2018 Jul 26;56(8):e00666-18
  • Diagnostic accuracy and prognostic value of simultaneous hybrid 18F-fluorodeoxyglucose positron emission tomography/magnetic resonance imaging in cardiac sarcoidosis. Wicks EC, et al Eur Heart J Cardiovasc Imaging. 2018 Jul 1;19(7):757-767
  • Genetic variants associated with susceptibility to idiopathic pulmonary fibrosis in people of European ancestry: a genome-wide association study. Allen RJ, et al. Lancet Respir Med. 2017 Nov;5(11):869-880
  • Rapid identification of a Mycobacterium tuberculosis full genetic drug resistance profile through whole genome sequencing directly from sputum. Nimmo C, et al Int J Infect Dis. 2017 Sep;62:44-46
  • Bioaerosol production by patients with tuberculosis during normal tidal breathing: implications for transmission risk. Wurie FB, et al Thorax. 2016 Jun;71(6):549-54.
  • Rapid Expansion of Human Epithelial Stem Cells Suitable for Airway Tissue Engineering. Butler CR, et al Am J Respir Crit Care Med. 2016 Jul 15;194(2):156-68
  • Role of a functional polymorphism in the F2R gene promoter in sarcoidosis. Platé M, et al Respirology. 2015 Nov;20(8):1285-7
  • What is the role for Xpert® MTB/RIF in high-resource settings? Experience from a central London hospital. Gupta RK, et al. Int J Tuberc Lung Dis. 2014 Nov;18(11):1323-6